| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥6,500,000)
Fiscal Year 1986: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1985: ¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1984: ¥3,500,000 (Direct Cost: ¥3,500,000)
|
|---|
| Research Abstract |
The purpose of this study is to investigate the role of Marek's disease tumor-associated surface antigen (MATSA) in tumor immunity. Various kinds of antigens are expressed on the cell surface of Marek's disease (MD) lymphoblastoid cell lines, including MD tumor-associated surface antigen (MATSA), chicken fetal antigen, thrombocyte antigen, major histocompatibility antigen and other antigens. In the present study, we examined the biochemical characteristics of MATSA expressed on MSB1-Clo.18 cells using a monoclonal antibody (2B9). The results are summarized as follows:
1. The reactivity of 2B9 to MATSA on transplantable MSB1-Clo.18 cells was inhibited by anti-MATSA rabbit serum at a maximum of 85.5 %, and lost by treatment of the cells with trypsin or pronase. The reactivity also decreased to about 80 % by treatment of the cells with tunicamycin.
2. The antigenic activity of MATSA was stable by heating at 37゜C for 30 minutes, but was unstable by heating at 56゜C for 30 minutes, and was lost by heating at 73゜C for 30 minutes. The activity was stable at neutrality or alkalinity, but was unstable at acidity below pH 6.0. Further, the activity decreased to 20-30 % by sodium metaperiodate treatment, but was stable by neuraminidase treatment. The purified MATSA was shown to have an apparent molecular weight of 70 kilodalton by SDS-PAGE analysis.
|
